Grounded in science, elevating the standard

TerrAscend’s co-founder and CEO, Dr. Michael Nashat, Pharm. D., has over 12 years of experience in patient care, quality assurance, medical and regulatory affairs and R&D. Prior to co-founding TerrAscend, Dr. Nashat cofounded and was the Executive Director of OnPharm Independent Pharmacy Group, the largest independent non banner group in Canada with over 500 pharmacies. Dr. Nashat is a former board member of the Canadian Association of Chain Drug Stores, Ontario College of Pharmacists and the Canadian Foundation for Pharmacy. Dr. Nashat is a former member of the Ontario Ministry of Health and Long Term Care’s Pharmacy Council and the former Vice Chair of the Ontario Pharmacists Association’s Owners Advisory Council. Dr Nashat received his Doctor of Pharmacy Magna Cum Laude from the Albany College of Pharmacy and Health Sciences and completed his Post-Doctoral Fellowship in Neuroscience Medical Strategy at Rutgers University and Bristol-Myers Squibb.

Matthew Johnson, a seasoned healthcare industry executive with over 25 years of experience, has held multiple senior-level positions with several large medical device and pharmaceutical companies. Most recently, he led the AbbVie Transition Office and was responsible for managing enterprise-wide transformation efforts, including merger integration. Prior to this, he headed Global Alliance Management within Abbott’s pharmaceuticals division where he drove collaboration strategy planning, alignment and communication among project teams for all of Abbott’s partnered pipeline products. He also held senior leadership roles at Brunswick Corporation and Baxter Healthcare Corporation.

Adam Kozak brings a wealth of experience from Loblaw Companies Limited.  During his 10-year tenure, Adam led initiatives in mergers and integration, process re-engineering and analytics. Prior to Loblaw, Adam also held positions at Deloitte and Wormald Masse Keen Lopinski.

Stacey has over 20 years of experience in marketing, communications, brand strategy, M&A integration, operations, and change management. She is inspired by companies that are values-driven and committed to having a positive impact on the world. She joined TerrAscend in April 2019, following over a decade of senior communications roles at McKinsey & Company. She has experience working in a wide range of industries, including architecture and engineering, fashion design, and financial services.

Brian has 20+ years of experience serving in investment transactional advisory, securities regulation, and compliance. Prior to joining TerrAscend, Brian held positions at Sound Point Capital Management and Fried Frank, Harris, Shriver & Jacobson.

Robyn Rabinovich is a business development professional with extensive experience in the cannabis space. Her knowledge supports her ability to evaluate business development opportunities within Canada and across the globe. Robyn obtained her International Business Degree from Dalhousie University.

Ari Unterman was formerly a corporate lawyer with experience in corporate and technology law. He has also participated in entrepreneurial and start up ventures, including supporting an early stage legal technology start up. Ari obtained his BA in Political Science at Western University and his JD/MBA at the University of Windsor.

Jason Wild is the President and Chief Investment Officer of JW Asset Management, LLC, and the advisor for five investment partnerships with approximately $1 billion in assets under management. Mr. Wild received his license as a pharmacist in 1997, and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the healthcare sector. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy. Mr. Wild is the Chairman of the Board of TerrAscend Corp. and Arbor Pharmaceuticals. He is a board member of Vensun Pharmaceuticals and Vitruvias Therapeutics. Funds managed by JW Asset Management, LLC are the largest shareholders in TerrAscend Corp. Mr. Wild is also a board member of NETA NJ LLC where he will be actively involved in planning and directing the organization’s strategic and long-range goals.

TerrAscend’s co-founder and CEO, Dr. Michael Nashat, Pharm. D., has over 12 years of experience in patient care, quality assurance, medical and regulatory affairs and R&D. Prior to co-founding TerrAscend, Dr. Nashat cofounded and was the Executive Director of OnPharm Independent Pharmacy Group, the largest independent non banner group in Canada with over 500 pharmacies. Dr. Nashat is a former board member of the Canadian Association of Chain Drug Stores, Ontario College of Pharmacists and the Canadian Foundation for Pharmacy. Dr. Nashat is a former member of the Ontario Ministry of Health and Long Term Care’s Pharmacy Council and the former Vice Chair of the Ontario Pharmacists Association’s Owners Advisory Council. Dr Nashat received his Doctor of Pharmacy Magna Cum Laude from the Albany College of Pharmacy and Health Sciences and completed his Post-Doctoral Fellowship in Neuroscience Medical Strategy at Rutgers University and Bristol-Myers Squibb.

Richard Mavrinac held positions as CFO for George Weston Limited and Executive VP of Loblaw Companies and has extensive expertise in public company finance and strategy.

Craig Collard is the CEO of Veloxis Pharmaceuticals, a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patient and has over 20 years of experience in the pharmaceutical industry. Mr. Collard has a proven track-record of leadership, managing organizational change, and driving successful merger and acquisition activity. Prior to Veloxis, Mr. Collard was the Founder and CEO of Cornerstone Therapeutics, a company focused on hospital, respiratory and adjacent specialty markets.

Lisa has 20+ years of experience in manufacturing, distribution, and retail, previously holding senior financial positions with some of Canada’s largest publicly-traded corporations. A strategic thinker with diverse experience in leading growth, Lisa has advised mid-market privately held companies in both the United States and Canada. Lisa holds a BA (Economics) from Western University, and an MBA from Queen’s University, and also holds the Institute of Corporate Directors ICD.D (Certified Director) designation.